GLIAPHARM
GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells , the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Their vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions. GliaPharm is a Swiss biotechnology company a... ctive in the development of treatments for neurological and psychiatric diseases. The innovative therapeutic approach of GliaPharm is to target glial cells , or 'support cells' of neurons, to support and improve brain metabolism under certain pathological conditions. Their vision is to become a leader in the development of glial cell targeting agents that act as neuroprotective agents and maintain cognitive functions.
GLIAPHARM
Social Links:
Industry:
Biotechnology Health Care
Founded:
2016-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.gliapharm.com
Total Employee:
11+
Status:
Active
Contact:
41 22 545 11 15
Email Addresses:
[email protected]
Total Funding:
2.18 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
FONGIT Innovation Fund
FONGIT Innovation Fund investment in Debt Financing - GliaPharm
Gliaven
Gliaven investment in Seed Round - GliaPharm
ACE & Company
ACE & Company investment in Seed Round - GliaPharm
MassChallenge
MassChallenge investment in Non Equity Assistance - GliaPharm
Official Site Inspections
http://www.gliapharm.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.83 K
- Host name: h2web76.infomaniak.ch
- IP address: 83.166.138.22
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "GliaPharm"
About Us - GliaPharm
Magistretti co-founded GliaPharm as a spinoff of three decades of research performed in his laboratory at EPFL with the objectives to clinically apply fundamental discoveries he has …See details»
GliaPharm - Crunchbase Company Profile & Funding
GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic …See details»
GliaPharm SA – Swiss Biotech
GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform …See details»
GliaPharm SA - BioAlps
GliaPharm’s innovative therapeutic approach is to target glial cells, the ‘support cells’ of neurons, to sustain and enhance brain metabolism in pathological conditions. Specialties. ...See details»
News - GliaPharm
Alzheimer’s disease: The Alzheimer’s Drug Discovery Foundation (ADDF) invests $4.2M in GliaPharm to advance its lead program Read more. Oct, 2022 Collaboration. UCB Read more. …See details»
The Alzheimer’s Drug Discovery Foundation invests …
The ADDF will invest $4.2 million to bring GliaPharm’s lead compound GP-119 to the clinical stage. GP-119 is a novel orally active small molecule that acts on brain energy metabolism. “This comes as a strong validation for GliaPharm’s …See details»
GliaPharm - Products, Competitors, Financials, Employees, …
GliaPharm focuses on the development of treatments for neurological and psychiatric disorders. Use the CB Insights Platform to explore GliaPharm's full profile. ... research and advocacy …See details»
GliaPharm - VentureRadar
GliaPharm is a Swiss-based startup company that develops treatments for neurological and psychiatric disorders. Our company is a spinoff from a leading research laboratory at EPFL. …See details»
GliaPharm Company Profile 2024: Valuation, Funding & Investors
GliaPharm General Information Description. Developer of treatments and therapies intended to address neurological and psychiatric disorders. The company specializes in the research and …See details»
GliaPharm SA at the Swiss Biotech Day
GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform and pipeline of molecules targeting brain …See details»
GliaPharm SA | Alzheimer's Drug Discovery Foundation
Jan 8, 2024 GliaPharm is a Swiss-based biotech company that develops small molecules that target astrocytes to stimulate brain energy metabolism in neurological diseases. Astrocyte …See details»
GliaXTM - GliaPharm
Technology Platform GliaXâ„¢ GliaPharm has established a proprietary drug discovery platform, GliaXâ„¢, centered on glial cells activity and brain metabolism.Through this platform, the …See details»
GliaPharm braces to enter the clinical phase - startupticker.ch
Feb 28, 2022 To accelerate drug development toward other neurological indications, GliaPharm and the Wyss Center, a non-profit organization dedicated to accelerating discoveries in …See details»
GliaPharm SA and the Wyss Center enter collaboration to develop …
Feb 24, 2022 Geneva, Switzerland – GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, and …See details»
Alzheimer Research: Gliapharm raises CHF 3.65 Million
Nov 29, 2024 GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, announces the …See details»
GliaPharm - EU-Startups
GliaPharm is a biotechnology business established in Switzerland that focuses on neurological and mental illnesses. In pathological settings, GliaPharm's novel treatment approach is to …See details»
GliaPharm SA and the Wyss Center Enter Collaboration to Develop …
Feb 24, 2022 GENEVA–(BUSINESS WIRE)–#Alzheimers–GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent …See details»
GliaPharm receives USD 4.2M to advance Alzheimer’s treatment
Dec 20, 2023 GliaPharm’s lead candidate, GP-119, is an orally active small molecule targeting this issue. The USD 4.2 million investment will support the progression of GP-119 through …See details»
Pipeline - GliaPharm
Pipeline Nature gave us glial cells. We unlock their potential. GliaPharm's pioneering approach is to stimulate energy utilization in the brain by targeting a type of glial cells called …See details»